Skip to Content
Søg Menu

First-line niraparib is associated with improvement in QA-PFS and QA-TWiST

According to the placebo-controlled trial PRIMA, patients with advanced ovarian cancer seem to benefit from the maintenance therapy with niraparib.

Ma Pilar Barretina-Ginesta

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Relateret indhold

Clare Scott

Outstanding results of ovarian cancer treatment

/ Clare Scott
ESMO22Gynækologisk cancer Play the Video 8:59
Kristina Lindemann

Optimizing the front-line PARP-inhibitor treatment of ovarian cancer from a Nordic perspective

/ Kristina Lindemann
ESMO22Gynækologisk cancerCancer Play the Video 2:10
Kristina Lindemann

ESMO Highlights: Promising data for the frontline treatment of gynecologic cancer

/ Kristina Lindemann
ESMO22Gynækologisk cancer Play the Video 7:19
Back to top